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Abstract 
Ramucirumab (Cyramza®), approved April 21, 2014, is a 
vascular endothelial growth factor receptor 2 (VEGFR2) an-
tagonist with a U.S. Food and Drug Administration (FDA) 
indication for the treatment of advanced or metastatic gas-
tric/gastroesophageal junction adenocarcinoma. Gastric can-
cer is a prevalent cancer in the United States with a poor 
prognosis. The phase 3 trial, REGARD, shows that ramu-
cirumab, when used within four months after the last dose of 
first-line chemotherapy or six months after the last dose of 
adjuvant chemotherapy, increases overall survival. Also, 
ramucirumab has been included in combination therapy, 
such as in the RAINBOW trial, which demonstrated its effec-
tiveness in combination with paclitaxel as a second-line 
treatment option. Notable adverse reactions to ramucirumab 
are severe hypertension and injection site reactions. Because 
it is a newer anticancer agent, ramucirumab's full potential 
may not yet be recognized. Possible future uses of ramu-
cirumab may include the treatment of other forms of cancer 
or utilization as a first-line agent 
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Introduction/Epidemiology 
Gastric cancer is one of the most prevalent cancers world-
wide, and is currently the 14th most common form of cancer 
in the United States.1.2 Adenocarcinoma-type gastric cancers 
account for 90 to 95 percent of all gastric malignancies. 
While gastric cancer is most commonly diagnosed in elderly 
patients, excluding those cancers affecting the gastric cardia, 
recent decades have revealed a nearly doubled incidence in 
gastric cancer among U.S. patients between the ages of 25 
and 36 years (0.27 up to 0.45 per 100,000 between 1977-
1981 to 2002-2006, respectively). Recent incidence rates for 
gastric adenocarcinomas involving the gastric cardia andl/or 
gastroesophageal junction are around two and 1.94 per 
100,000, respectively.2 The American Cancer Society projects 
that in the United States there will be 22,220 new cases and 
10,990 deaths due to gastric cancers for the year 2014.3 
Gastric cancer is often difficult to detect until later stages of 
development, and only 10 to 20 percent of cases are diag-
nosed in an early stage. Therefore, most patients do not pre-
sent until the cancer has already metastasized.2,4 At best, 
five-year survival is typically around SO percent for cases 
localized in distal regions of the stomach. Five-year survival 
drops to almost 0 percent for nonlocalized distal cases and is 
10 to 15 percent for cases involving proximal regions of the 
stomach. Thus, it is recommended that high risk individuals 
undergo routine screening to monitor for development of 
gastric cancer.4 
Known risk factors that contribute to the development of 
gastric cancer include: age (most common between 60 and 
80 years), male gender and a family history of gastric can-
cer.1.2 Lifestyle factors contributing to gastric cancer include 
a diet low in fruits and vegetables and/or high in salted and 
preserved foods, smoking and certain industrial occupations. 
1
•
4 Gastric cancers also tend to be more prevalent among indi-
viduals of African, Asian and Native American descent. 
Current treatments of gastric cancer include surgery, 
radiotherapy, chemotherapy and, most recently, targeted 
therapy.t.4 With utilization of first-line agents including fluor-
opyrimidine, platinum and surgery, there will still be over 
10,000 deaths in the United States in 2014 directly caused by 
gastric cancer. Consequently, new treatment options with 
improved efficacy toward gastric cancer are needed. Trials of 
drugs such as bevacizumab (a monoclonal antibody targeting 
vascular endothelial growth factor A (VEGF-A) to inhibit an-
giogenesis) have been conducted to evaluate alternative 
mechanisms to successfully treat gastric cancer and thus re-
duce mortality. Ramucirumab, a monoclonal antibody target-
ing the vascular endothelial growth factor receptor (VEGFR), 
is the latest angiogenesis inhibitor that helps to increase the 
survival rate of gastric cancer patients. This novel mecha-
nism categorizes ramucirumab as targeted therapy, which 
provides a new and unique treatment option for gastric can-
cer to prolong survival. 
Pathophysiology 
There is a well-documented correlation between Helicobac-
ter pylori (H. pylori) infections and development of gastric 
cancer.U These gram-negative bacteria are associated with 
cases of severe and chronic gastritis as they secrete a 
number of substances such as proteases, phospholipases, 
ammonia, acetaldehyde and reactive oxygen species that are 
capable of inducing histological and genetic changes. These 
alterations lead to malignant cell growth in infected areas of 
the stomach. This can initiate a cascade of histopathological 
changes in gastric mucosa leading to the development of a 
gastric malignancy, particularly in patients with genetic sus-
ceptibility and poor diet. 
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Gastric adenocarcinoma presents in two histologically 
distinct forms: intestinal and diffuse.1 Intestinal gastric ade-
nocarcinomas form differentiated clusters of cohesive neo-
plastic cells that easily ulcerate. This type tends to have a 
better prognosis and is more common in the elderly, males 
and African Americans. It is also heavily influenced by envi-
ronmental factors, including diet, H. pylori infections and 
obesity. Diffuse gastric adenocarcinomas are not as differen-
tiated and, instead, manifest as a generalized thickening of 
the stomach wall. Diffuse-type is more common in females, 
younger patients and may have a genetic predisposing factor 
linked with type A blood. Advanced or invasive gastric ade-
nocarcinomas develop along a cascade of histological chang-
es.s Initially, atrophy of the stomach lining leads to changes 
in the parietal cells, which is followed by intestinal metapla-
sia where the normal gastric cells begin to display an intesti-
nal cell phenotype. Lastly, neoplastic intestinal dysplasia 
develops and may lead to carcinoma in the affected area. This 
cascade is more relevant to intestinal-type carcinomas ver-
sus diffuse-type. 
The link to family history and the actions of H. pylori indicate 
that a number of inherited and pathologically induced genet-
ic changes can lead to the onset of gastric adenocarcinoma.1 
Investigators have determined that, on average, 4.18 gene 
changes are needed. Mutations in p27, p53, the K-ras onco-
gene and various cell signaling pathways are commonly seen. 
More aggressive gastric adenocarcinomas also develop the 
ability to express VEGF leading to an increased incidence of 
metastasis. 
Clinical Presentation 
As previously mentioned, gastric adenocarcinomas are often 
difficult to detect in early stages as patients are often asymp-
tomatic.4 In approximately 50 percent of cases, patients pre-
sent with minor symptoms, such as dyspepsia, which are 
associated with a wide variety of gastrointestinal ailments. 
Due to the lack of symptom manifestation, 80 percent to 90 
percent of patients present with locally advanced or meta-
static tumors and complain of anorexia and weight loss as 
well as abdominal pain. Nausea and vomiting can occur with 
obstructive tumors while ulcerated tumors may cause bleed-
ing that leads to hematemesis, melena and gastrointestinal 
hemorrhaging. Palpable masses, cachexia, bowel obstruction, 
ascites, hepatomegaly and lower extremity edema can also 
indicate advanced gastric adenocarcinoma. In these instanc-
es, the tumor has often already metastasized to neighboring 
structures and/or lymph nodes. 
Treatment 
Surgical intervention is the p1imary means of treating gastric 
adenocarcinomas.2 Given the high incidence of presentation 
in advanced stages of the disease, surgery is often comple-
mented with adjuvant radio- and/or chemotherapy. Surgery 
can be performed for cases with a localized tumor in the 
stomach and for cases limited to local node involvement. 
Cases with distal node involvement or metastasis to other 
structures outside the stomach often necessitate adjuvant or 
neoadjuvant chemotherapy. Stage Ill patients require radical 
surgery followed by chemoradiation therapy, while patients 
presenting at stage IV typically receive intensive palliative 
chemotherapy and radiotherapy. 
Chemotherapeutic agents commonly used in the treatment 
and palliation of gastric cancers include 5-tluorouracil 
(5-FU), methotrexate, docetaxel and cisplatin.2 Methotrexate 
and 5-FU are antimetabolites that disrupt normal deoxyribo-
nucleic acid (DNA) synthesis while cisplatin is a platinum-
containing alkylating agent that acts to directly damage DNA. 
Docetaxel is a taxane compound that interferes with mitosis.6 
There are multiple standard combination protocols as well as 
numerous clinical trials underway evaluating new combina-
tion protocols.2, 7 Recent progress in the development of tar-
geted therapies has led to an increase in studies for potential 
future treatments of a wide variety of cancers including 
gastric. Several drugs showing significant promise in the 
treatment of advanced gastric cancer include the monoclonal 
antibodies trastuzumab (for HER-2 positive cancers) and 
ramucirumab (anti-VEGFR2).8.9 
Indications and Mechanism of Action 
Ramucirumab is approved for the treatment of advanced or 
metastatic gastric or gastroesophageal junction adenocarci-
noma as a single agent.to This treatment regimen should be 
used if disease progression occurs with or after tluoropyrimi-
dine- or platinum-containing chemotherapy.11 Ramucirumab 
is an antineoplastic agent and a recombinant monoclonal 
antibody in the lgGl class.10,11 The drug binds to the vascular 
endothelial growth factor receptor 2 (VEGFR2) with a high 
affinity.11 By binding to the VEGFR2 receptor, ramucirumab 
blocks the binding of VEGFR ligands, including VEGF-A, 
VEGF-C, and VEGF-D, which inhibits the activation of the re-
ceptor. Ligand-induced proliferation and migration of endo-
thelial cells are inhibited. Therefore, tumor vascularity and 
growth are reduced. Ramucirumab does not affect initial lev-
els ofVEGF ligands, unlike bevacizumab, another VEGF inhib-
itor (which binds to the ligand VEGF itself).12 By antagonizing 
the receptor rather than binding the ligand, ramucirumab 
may have less resistance. 
Pharmacokinetics 
Ramucirumab is given intravenously (IV) at a dose of 
8mg/kg every two weeks.12 The half-life of ramucirumab at 
steady-state is 200 to 300 hours and accumulates with in-
creasing doses.12. 13 A phase 1 clinical trial conducted by 
Spratlin and colleagues studied the pharmacokinetics and 
pharmacodynamics of ramucirumab.13 Patients with ad-
vanced solid malignancies received escalating doses of ramu-
cirumab as a one hour intravenous infusion. The clearance 
rate of ramucirumab decreased disproportionately as the 
dose was increased. This nonlinear effect suggests that the 
drug is eliminated by saturable receptor-mediated clear-
ance.12. 13 There have not yet been studies evaluating the ef-
fects of hepatic or renal impairment on the pharmacokinetics 
of ramucirumab.12 The trial by Spratlin and colleagues also 
showed that circulating VEGF-A concentrations increased 
almost immediately after treatment to 1.5- to 3.5-fold higher 
than pretreatment concentrations and remained elevated 
until the next treatment.13 As long as ramucirumab was pre-
sent, VEGF-A levels remained elevated. The soluble vascular 
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endothelial growth factor receptors one and two (sVEGFR-1 
and sVEGFR-2) concentrations tended to decrease immedi-
ately after ramucirumab was administered, but they recov-
ered to near-pretreatment levels. Neither the VEGF-A, 
sVEGFR-1 or sVEGFR-2 levels were related to the dose of 
ramucirumab. The pharmacokinetic profile of ramucirumab 
suggests that weekly dose administrations of the drug are 
biologically relevant The minimum target trough level was 
selected to be greater than or equal to 20 µg/mL basedl on 
the pharmacodynamic and efficacy data gathered from hu-
man tumor xenografts implanted in mice. This trough level 
was achieved in all the treated patients from this trial. 
Adverse Events/Toxicity 
The most prevalent adverse events observed in patients 
were hypertension, diarrhea, anemia and infusion-related 
reactions.11 Hypertension occurred in 16 percent of patients 
with 8 percent of patients experiencing grade 3 or 4, which is 
classified as severe with a blood pressure reading of greater 
than or equal to 180/llOmm Hg (versus a grade 1 or 2, 
which is considered mild to moderate with a blood pressure 
reading of 140 to 179/90 to 109mm Hg).11·14 The current 
recommendation is to temporarily stop the infusion until the 
hypertension is controlled with antihypertensive medication 
or to permanently discontinue ramucirumab infusion if the 
hypertension is severe and uncontrolled.11 The infusion reac-
tions associated with ramucirumab, which usually occur with 
the first or second infusion, include chills, flushing, hypoten-
sion, bronchospasm, dyspnea, hypoxia, wheezing, chest pain 
or tightness, supraventricular tachycardia, back pain or 
spasms, rigors or tremors, and paresthesia. Patients should 
be continuously monitored for infusion reaction symptoms 
and the treatment should be immediately and permanently 
discontinued for grade 3 or 4 reactions. Ramucirumab was 
shown to increase the risk of hemorrhage, including cases of 
severe and fatal bleeding. Consequently, in the United States, 
a black box warning for ramucirumab exists, which states 
that it should be permanently discontinued in patients who 
experience serious hemorrhagic events. Other serious ad-
verse events that have occurred in patients receiving ramu-
cirumab include arterial thrombotic events, gastrointestinal 
perforation, and reversible posterior leukoencephalopathy 
syndrome, which causes lesions in the parieto-occipital re-
gions of the cerebral hemispheres and is characterized by 
altered mental status, headache, seizure and visual disturb-
ances.11.1s If any of these events occur, it is recommended to 
discontinue treatment.11 Wound healing impairment is com-
monly seen in patients who are receiving antiangiogenic 
therapy; however, ramucirumab has not yet been studied in 
patients with serious or nonhealing wounds. It is recom-
mended to stop treatment prior to, during and after treat-
ment of such wounds and to continue ramucirumab infusions 
only when the wound is fully healed. 
Drug interaction studies have not yet been conducted with 
ramucirumab. However, based on its therapeutic category, 
there are several drugs that should be avoided while on 
ramucirumab.12 Monoclonal antibodies have been shown to 
enhance adverse and toxic effects of belimumab, an IgGl-
lambda monoclonal antibody that blocks binding of soluble 
human B lymphocyte stimulator protein to receptors on B 
lymphocytes (and therefore preventing the survival of B lym-
phocytes), so it has a risk factor of X (avoid combination with 
ramucirumab).11•16The adverse and toxic effects of bisphos-
phonate derivatives such as alendronate and ibandronate 
may be enhanced by systemic angiogenesis inhibitors, which 
gives them a risk factor of C (monitor therapy when used 
with ramucirumab). 
REGARD Trial: Patient survival rate 
Ramucirumab monotherapy for previously treated advanced 
gastric or gastroesophageal junction adenocarcinoma was 
evaluated in an international randomized, multicenter, place-
bo-controlled, phase 3 trial .17 Also known as REGARD, this is 
the trial that led to the FDA approval of ramucirumab. The 
purpose of the trial was to quantify the advantage in survival 
rate in patients who received ramucirumab versus those who 
did not With a sample size of 355 patients and a 2:1 ratio of 
those who received ramucirumab versus placebo, there was 
an increased median overall survival rate in those receiving 
ramucirumab of 5.2 months versus 3.8 months for the place-
bo group. The study was conducted as a double-blind, ran-
domized placebo-controlled trial in 29 countries all across 
the world. Inclusion criteria for the study gathered patients 
ages 24 to 87 with gastric adenocarcinoma, disease progres-
sion within the past four months of prior treatment, and an 
eastern cooperative oncology group (ECOG; see Table 1) per-
formance score of 0 or 1.u.1s Exclusion criteria included 
grade 3 or higher gastrointestinal (GI) bleeding within three 
months of randomization, arterial thromboembolic events 
within six months of randomization and uncontrolled hyper-
tension.17 All parties involved were masked except for in 
emergencies only. Every patient received recommended sup-
portive care, excluding any additional investigational drugs, 
and received ramucirumab or placebo until confirmed dis-
ease progression, intolerable toxicity or death. The primary 
measure within the study was overall survival rate. Second-
ary measures included rates of adverse effects and progres-
sion-free intervals. Tumor and quality of life assessments 
were also obtained. Results of the study concluded that 
ramucirumab therapy was superior to placebo therapy. Not 
only did the study conclude that the drug increased the over-
all survival rate, but also that the risk of death and disease 
progression were reduced between the two groups. These 
results, along with ramucirumab's unique mechanism of ac-
tion compared to other drugs used to treat gastric cancer, 
prompted the indication for second-line treatment of gastric 
or gastroesophageal adenocarcinoma. When overall survival 
rates with ramucirumab therapy were compared to those of 
bevacizumab (a monoclonal antibody targeting VEFG-A), 
bevacizumab had slightly better rates, which was deemed to 
be statistically insignificant. 
RAINBOW Trial: Combination Therapy 
A double-blind, randomized phase 3 trial, ramucirumab plus 
placlitaxel versus placebo plus paclitaxel in patients with 
previously treated advanced gastric or gastroesophageal 
junction adenocarcinoma, was conducted by Wilke and col-
leagues.19 Also known as the RAINBOW trial, this study eval-
uated the effects of ramucirumab in combination with 
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Table 1. Eastern Cooperative Oncology Group (ECOG) Performance Scale. 
Grade ECOG 
0 Fully active, able to carry on all pre-disease performance without restriction. 
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary 
nature; e.g., light housework, office work 
2 Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% 
of waking hours. 
3 Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. 
4 Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 
5 Dead. 
As published in Am. J. Clin. Oncol.: Oken, M.M., Creech, R.H., Tormey, D.C., Horton, ]., Davis, T.E., McFadden, E.T., Carbone, P.P.: 
Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am f Clin Oneal 5:649-655, 1982. 
The ECOG Performance Status is in the public domain and therefore available for public use. To duplicate the scale, please 
cite the reference above and credit the Eastern Cooperative Oncology Group, Robert Comis M.D., Group Chair. 
paclitaxel in patients with previously treated advanced gas-
tric cancer. The objective of the study was to determine if 
overall survival rate increased in patients treated with ramu-
cirumab plus paclitaxel versus placebo plus paclitaxel. In ithis 
placebo-controlled, multicentered phase 3 trial, patients who 
had disease progression within four months after platinum 
plus fluoropyrimidine with or without an anthracycline as a 
first-line chemotherapy treatment were eligible for the trial. 
Patients were randomized to receive either 8mg/kg of ramu-
cirumab or a placebo intravenously on days 1 and 15, and 
both groups received paclitaxel 80mg/m2 intravenously on 
days 1, 8 and 15 of a 28-day cycle. The primary endpoint was 
overall survival of the patients. The overall survival rate 
among the patients in the ramucirumab plus paclitaxel group 
was significantly higher than in the control group, with medi-
an survival periods of 9.6 and 7.4 months, respectively. Fur-
ther, the 12-month overall survival rate was 40 percent in 
the ramucirumab group and 30 percent in the control group. 
Taken together, the findings suggest that this combination 
therapy could become a new standard second-line treatment 
for patients with advanced gastric cancer. In addition, alt-
hough this particular study is complete, 13 patients in the 
ramucirumab plus paclitaxel group and seven in the control 
group are continuing to receive their respective treatments 
in order to evaluate an extension phase of the study to deter-
mine the long-term results of the treatments. 
Handling of Ramucirumab 
Vials of ramucirumab are supplied in a concentration of 
10mg/ml, and the calculated dose should be diluted with 
normal saline.2° Ramucirumab is not stable in solutions con-
taining dextrose. The mixture should be inverted to ensure 
even displacement in a final volume of 250mL. Ramucirumab 
should be stored under refrigeration at a temperature 
between 2 degrees and 8 degrees Celsius (36 degrees to 46 
degrees Fahrenheit). The diluted mixture should be stored 
no longer than 24 hours. When preparing ramucirumab, it is 
important to ensure quality by inspecting vials for any discol-
oration or loose particles.21 If present, discard the vial imme-
diately. Any unused ramucirumab, as well as supplies used 
for preparation and administration, and any patient or 
equipment waste, should be discarded in indicated yellow 
chemotherapy bins for incineration or according to company 
policy. 
Standard dosing of ramucirumab is 8mg/kg every two 
weeks.20 This should continue unless the disease progresses 
or there is evidence of unacceptable toxicity. Before admin-
istering ramucirumab, pre-medicate the patient with an Hl 
antagonist such as diphenhydramine. If the patient has expe-
rienced a grade 1 or 2 reaction previously, also medicate 
with dexamethasone and acetaminophen before ramu-
cirumab is initiated. The patient should be pre-medicated at 
an appropriate interval prior to administering ramucirumab 
in order to ensure optimal patient comfort and tolerance lev-
el. Diphenhydramine may only take five minutes to take 
effect if given JV, but up to two hours if taken orally. Similar-
ly, dexamethasone should be administered anywhere from 
15 to 30 minutes before treatment initiation, and acetamino-
phen can be administered five to 10 minutes before.11 
The infusion itself takes place over 60 minutes through a 
single infusion line. Ramucirumab should not be infused in 
the same IV line as electrolytes or other medications, and 
should not be given as an IV push.20 During administration, it 
is important to monitor for any infusion reactions: signs of 
tremors, back pain, chest pain and tightness, chills, flushing, 
dyspnea, hypoxia and paresthesia. More serious cases of in-
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fusion reactions include bronchospasms, hypotension and 
supraventricular tachycardia. Close monitoring is required at 
every administration of ramucirumab as the incidence of 
infusion-related reactions is slightly more prevalent in the 
first or second administration but presents a risk throughout 
treatment. If a grade 1 or 2 infusion reaction occurs, reduce 
the infusion rate by 50 percent and continue treatment. If a 
grade 3 or 4 reaction presents itself, permanently discontin-
ue ramucirumab.11 
Safety for Health Care Professionals 
While the effects of ramucirumab on patients are document-
ed, the effects on those who prepare, administer and dispose 
of the drug are not Occupational exposure to hazardous 
drugs, namely chemotherapy, are highest in pharmacists 
during its preparation and nurses during its administra-
tion.21 Lack of chemotherapy precautions at any stage of drug 
handling can result in hair loss, contact dermatitis and skin 
injury in the short term, as well as a higher rate of genotoxi-
city, cancer, fetal Joss and infertility in the long term. Appro-
priate precautions include the use of specific safety cabinets 
for preparation and appropriate personal protective equip-
ment (PPE). For preparation, this includes a ventilated cabi-
net that takes both employee safety and product sterility into 
account, which includes proper disposal of vapors and air 
circulation. Further precautions include wearing two pairs of 
chemotherapy-tested gloves to safeguard the preparer 
against any potential contact with the drug or waste 
contents, a chemotherapy-tested gown and a face shield or 
respirator if there is any risk of inhalation or splattering of 
chemotherapy agents. These same necessities carry to the 
bedside when nurses administer antineoplastic agents in-
cluding further precautions such as using needleless systems 
and ensuring that IV tubing is primed with normal saJine or a 
nonhazardous drug by a pharmacist prior to patient admin-
istration. Identical precautions are needed in order to dis-
pose of bodily fluids from a patient receiving chemotherapy, 
in addition to placing an absorbent pad over the toilet w!hen 
flushing in order to prevent splashing and contact.22 Disposal 
of any equipment used in the administration of ramucirumab 
or care of a patient receiving treatment should be placed in a 
biohazard bag and be placed in a yellow chemotherapy bin 
for incineration. This includes absorbent pads, IV tubing and 
any PPE. Any sharps or needles used in administration or 
maintenance of ramucirumab should be placed in a specified 
chemotherapy sharps container for proper disposal and in-
cineration.21 These precautions should persist after the inmal 
treatment, as chemotherapy and other hazardous drugs 
remain in the patient's body for up to 48 hours and are sub-
sequently excreted through waste such as urine, stool and 
emesis. Education on similar precautions, as well as disposal 
methods, should be provided to the family and caregivers of 
those on chemotherapy in order to prevent any accidental 
exposure.22 
Management of Adverse Effects 
As stated earlier, hypertension is one of the most clinically 
significant adverse effects of ramucirumab.11 Any existing 
hypertension should be well-controlled before treatment is 
initiated, and blood pressure should be monitored starting 
two weeks prior to infusion initiation and continued every 
two weeks throughout the course of therapy. More frequent 
monitoring may be indicated if the patient has a history of 
hypertension or if the patient develops hypertension over 
the course of ramucirumab administration.20 If a hyperten-
sive crisis occurs, immediate medical intervention, such as 
nitroprusside administration, may be indicated, although 
side effects must also be monitored.23 Educating patients on 
measuring their blood pressure at home may help prevent a 
hypertensive crisis from occurring. It is also important to 
ensure that patients are aware of side effects, such as flush-
ing. headaches and heart palpitations, which may indicate a 
hypertensive crisis. This knowledge, as well as health care 
provider contact information, may help patients avoid a cri-
sis and follow a medication regimen that effectively controls 
their blood pressure. Education on medication compliance, 
as well as lifestyle modifications, may provide additional 
benefit over the course of treatment. 
The incidence of bleeding and hemorrhage risk in those 
taking ramucirumab is slightly increased over those who 
received a placebo.20 A proactive approach to this adverse 
effect is prevention and, consequently, the use of bleeding 
precaution procedures should be followed in both the health 
care setting and as the patient is discharged. This involves 
avoiding unnecessary invasive procedures, such as rectal 
temperatures. In addition, the use of small gauge needles and 
direct pressure on bleeding sites for up to five minutes may 
help with clotting.23 Monitoring blood counts for abnormal 
values in platelets or prothrombin time, as well as hemoglo-
bin and hematocrit values that may indicate an internal 
bleed, is crucial. Observing trends in vital signs while the pa-
tient is in the hospital to monitor for signs of tachycardia and 
hypotension may alert health care providers to any potential 
hypovolemia indicating the presence of an internal bleed. 
Related to personal hygiene, soft toothbrushes and safety 
razors should be used. Any sharp corners that may cause 
bleeding should be covered in padding. Patients should re-
ceive education on providing these safety measures at home, 
as well as observing for abnormal bruising or feelings of diz-
ziness and heart palpitations. Patients should be instructed 
to immediately report to their health care provider if they 
notice any of these symptoms. 
Cancer-related fatigue (CRF), while comparable among the 
treatment modalities, still affects 36 percent of patients on 
ramucirumab.23 Cancer-related fatigue is defined by Horne-
ber et al. as "the syndrome of fatigue and exhaustion in can-
cer patients."24 This syndrome affects all aspects of health 
and manifests itself not only by a Jack of energy, but also by a 
loss of drive and social withdrawal in addition to impaired 
concentration and memory Joss. Many of these symptoms are 
subjective and can be identified by thorough communication 
between the patient and the health care provider. Symptoms 
may not be directly observed due to a focus on the treatment 
modality of the cancer itself, or they may not be reported if 
the patient withholds information due to fear of judgment or 
delay in treatment A degree of patient trust, as well as con-
stant follow-up, may help providers to diagnose CRF more 
readily and, consequently, facilitate initiation of appropriate 
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treatment. Of all the side effects that accompany cancer pa-
tients undergoing treatment, CRF is considered the worst 
due to its severe debilitation on the patient's quality of life. It 
can occur at any stage of the disease process including after 
admission. Proper education on CRF as a condition is impera-
tive for treatment as patients who recognize the symptoms 
are more open to treatment options. 
While pharmacological components such as hematopoietic 
growth factors and corticosteroids may improve CRF, they 
are only effective for a minority of patients and are often a 
short-term solution with added risks. However, nonpharma-
cologic activities such as physical exercise may provide the 
same benefits without as many of the risks. In a meta-
analysis completed by McMillan and Newhouse, it was shown 
that all modes of physical activity, especially aerobic exer-
cise, and to a lesser degree resistance exercise, may help not 
only decrease the manifestations of CRF, but also the symp-
tom clusters that accompany it such as depression and anxie-
ty.2s Improvement in cardiac reserve, lung ventilation and 
perfusion may explain such changes, especially since such 
characteristics are diminished in cancer patients both during 
and after treatment. 
Conclusion 
Gastric cancer is a prevalent disease that has a very low 
survival rate once it becomes advanced or metastatic. Once 
disease progression has led to metastasis, survival rates sig-
nificantly drop despite the utilization of first-line therapies. 
Ramucirumab is a monoclonal antibody that targets VEGF 
receptors and is used for the treatment of advanced or meta-
static gastric or gastroesophageal junction adenocarcinoma as 
a single agent. Through studies such as REGARD and RAIN-
BOW, ramucirumab has been shown to be an effective second-
line therapy as monotherapy or combination therapy with 
paclitaxel in prolonging survival over placebo. Ramucirumab 
is a novel anticancer agent, as treatment with this agent is 
categorized as "targeted therapy." However, its application in 
other types of cancer should also be considered. Because of 
the efficacy demonstrated by ramucirumab, it is crucial for 
health care professionals to properly manage adverse effects, 
such as hypertension and hemorrhage, to allow continuation 
and success of ramucirumab therapy in the treatment of gas-
tric or gastroesophageal junction adenocarcinoma. 
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